Atlas Molecular Pharma recibe la aprobación de la Administración de Drogas y Alimentos de los Estados Unidos de un medicamento huérfano para el tratamiento de la porfiria eritropoyética congénita

Atlas Molecular Pharma, una empresa privada fundada en 2015 en Derio (España) como un spin-off del Centro de Investigación Cooperativa en Biociencias (CIC bioGUNE), anunció hoy el reconocimiento por parte de la Administración de Drogas y Alimentos de los Estados Unidos (FDA) de Ciclopirox (AMP-L2.7. D7) como medicamento huérfano (Orphan Drug Designation-ODD) para el tratamiento [...]

2018-04-23T11:30:37+00:00 April 20th, 2018|News|

Atlas Molecular Pharma receives approval by the US Food & Drug Administration of an Orphan Drug for the treatment of Congenital Erythropoietic Porphyria

Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today that the US Food & Drug Administration has granted the designation as Orphan-Drug of AMP-L2.7.D7 (ciclopirox) for treatment of Congenital Erythropoietic Porphyria. This recognition occurs only a few [...]

2018-04-23T11:27:47+00:00 April 20th, 2018|News|

ATLAS Molecular Pharma awarded with the research grant ‘Cristina Pericàs Almendro’ 2018-2019 by the Spanish Association for Creutzfeldt-Jakob disease

The Spanish association for Creutzfeldt-Jakob disease (AECJD) gathers patients and relatives dealing with devastating prion disorders and aims to contribute to a cure by promoting research activities. For that purpose, the members have organized several fundraising activities and opened a call for researchers all over Spain to apply to ‘Cristina Pericàs Almendro’ 2018-2019 research grant. [...]

2018-03-16T09:34:44+00:00 March 16th, 2018|News|

Atlas Molecular Pharma recibe la aprobación de la Comisión Europea de un medicamento huérfano para el tratamiento de la Porfiria Eritropoyética Congénita

DERIO, España.- Atlas Molecular Pharma, una empresa privada fundada en 2015 en Derio (España) como un spin-off del Centro de Investigación Cooperativa en Biociencias (CIC bioGUNE), anunció hoy la confirmación y aprobación por parte de la Comisión Europea de Ciclopirox (AMP-L2.7. D7) como medicamento huérfano (Orphan Medicinal Product-OMP) para el tratamiento de la Porfiria Eritropoyetica [...]

2018-01-22T21:40:26+00:00 January 22nd, 2018|News|

Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria

DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today the confirmation and approval by the European Commission of Ciclopirox (AMP-L2.7.D7) as an Orphan Medicinal Product (OMP) for the treatment of Congenital Erythropoietic Porphyria. This is a follow [...]

2018-01-22T21:32:21+00:00 January 22nd, 2018|News|

La EMA (Agencia Europea del Medicamento) se pronuncia favorablemente sobre la designación de fármaco huérfano a una molécula con actividad frente a la Porfíria Eritropoyética Congénita, desarrollada por CIC bioGUNE y ATLAS Molecular Pharma

El Comité para la designación de medicamentos huérfanos (COMP) de la Agencia Europea del Medicamento (EMA) comunica a la compañía vasca Atlas Molecular Pharma S. L. su opinión favorable a la solicitud del fármaco L2.7.D7 para el tratamiento de la Porfiria Eritropoyética Congénita (PEC). La EMA otorga este reconocimiento tras un riguroso examen de los [...]

2018-01-22T21:41:23+00:00 December 14th, 2017|News|

Atlas Molecular Pharma Receives European Medicines Agency (EMA) Orphan Designation for Congenital Erythropoietic Porphyria

DERIO, Spain.- Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), announced today a favourable report, as Orphan Medicinal Product, from the European Medicines Agency (EMA) for its candidate drug (L2.7.D7) for the treatment of Congenital Erythropoietic Porphyria. “The favorable [...]

2018-01-22T21:24:46+00:00 December 14th, 2017|News|

ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)

ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of technology-based companies and it takes into account the creation of new technology and the innovation character of the business initiative.

2017-03-07T19:47:38+00:00 March 14th, 2017|News|

A possible pharmacological chaperone for congenital erythropoietic porphyria

The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. See also “Una molécula ‘carabina’ para aplacar la porfiria congénita”.

2017-03-06T11:37:51+00:00 March 6th, 2017|News|